References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
- Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
- Chu Q, Vincent M, Logan D, et al. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 2005;50:355–374.
- Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–1598.
- Van ZL, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19:125–141.
- Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm. 1994;51:3058–3060.
- Bernabeu E, Cagel M, Lagomarsino E, et al. Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm. 2017;526:474.
- Cabanes A, Briggs KE, Gokhale PC, et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998;12:1035.
- Sharma A, Straubinger RM, Ojima I, et al. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci. 1995;84:1400.
- Bartoli MH, Boitard M, Fessi H, et al. In vitro and in vivo antitumoral activity of free, and encapsulated taxol. J Microencapsul. 1990;7:191–197.
- Sharma A, Sharma US, Straubinger RM. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996;107:265–272.
- Sharma A, Straubinger RM. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res. 1994;11:889–896.
- Koudelka S, Turanek J. Liposomal paclitaxel formulations. J Control Release. 2012;163:322–334.
- Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009;63:603.
- Wang X, Zhou J, Wang Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer. 2010;46:1474.
- Wang X, Zheng H, Zhu Z, et al. Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. J Pharm Sci. 2010;99:4746.
- Najeeb S, Zafar MS, Khurshid Z, et al. Applications of polyetheretherketone (PEEK) in oral implantology and prosthodontics. J Prosthodont Res. 2016;60:12–19.
- Qu G, Liu S, Zhang S, et al. Graphene oxide induces toll-like receptor 4 (TLR4)-dependent necrosis in macrophages. ACS Nano. 2013;7:5732.
- Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 2008;68:492–497.
- Patel P, Clarke C, Barraclough DL, et al. Metastasis-promoting anterior gradient 2 protein has a dimeric thioredoxin fold structure and a role in cell adhesion. J Mol Biol. 2013;425:929–943.
- Z H, Y G, B H, et al. Knockdown of AGR2 induces cellular senescence in prostate cancer cells. Carcinogenesis. 2012;33:1178.
- Duhm J, Göbel BO. Role of the furosemide-sensitive Na+/K + transport system in determining the steady-state Na + and K + content and volume of human erythrocytes in vitro and in vivo. J Membrain Biol. 1984;77:243.
- Geck P, Pfeiffer B. Na+ + K+ + 2Cl- cotransport in animal cells-its role in volume regulation. Ann N Y Acad Sci. 1985;456:166–182.
- Klein JD, Perry PB, O’Neill WC. Regulation by cell volume of Na(+)-K(+)-2Cl- cotransport in vascular endothelial cells: role of protein phosphorylation. J Membarin Biol. 1993;132:243–252.
- Iwamoto LM, Fujiwara N, Nakamura KT, et al. Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. Am J Physiol Lung Cell Mol Physiol. 2004;287:L510.
- Zhou Y, Sun W, Chen N, et al. Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis. Oncotarget 2017;8:66328–66342.
- Cai H, Reim K, Varoqueaux F, et al. Complexin II plays a positive role in Ca2+-triggered exocytosis by facilitating vesicle priming. Proc Natl Acad Sci USA. 2008;105:19538.
- Komatsu H, Kakehashi A, Nishiyama N, et al. Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors. Cbm. 2013;13:171–180.
- Dong A, Gupta A, Pai RK, et al. The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation. J Biol Chem. 2011;286:18301.
- Zhao B, Li L, Lei Q, et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862.